Pharmacokinetics of HIV-Integrase Inhibitors During Pregnancy: Mechanisms, Clinical Implications and Knowledge Gaps

Clinical Pharmacokinetics
Ruben van der GaliënDavid M Burger


Prevention of mother-to-child transmission of HIV and optimal maternal treatment are the most important goals of antiretroviral therapy in pregnant women with HIV. These goals may be at risk due to possible reduced exposure during pregnancy caused by physiological changes. Limited information is available on the impact of these physiological changes. This is especially true for HIV-integrase inhibitors, a relatively new class of drugs, recommended first-line agents and hence used by a large proportion of HIV-infected patients. Therefore, the objective of this review is to provide a detailed overview of the pharmacokinetics of HIV-integrase inhibitors in pregnancy. Second, this review defines potential causes for the change in pharmacokinetics of HIV-integrase inhibitors during pregnancy. Despite increased clearance, for raltegravir 400 mg twice daily and dolutegravir 50 mg once daily, exposure during pregnancy seems adequate; however, for elvitegravir, the proposed minimal effective concentration is not reached during pregnancy. Lower exposure to these drugs may be caused by increased hormone levels and, subsequently, enhanced drug metabolism during pregnancy. The pharmacokinetics of bictegravir and cabotegravir, which are unde...Continue Reading


Jan 1, 1977·Clinical Pharmacokinetics·T F Blaschke
Sep 1, 1986·British Journal of Clinical Pharmacology·J O MinersD J Birkett
Jul 1, 1984·European Journal of Drug Metabolism and Pharmacokinetics·F KellerA Distler
Jan 1, 1984·Clinical Pharmacokinetics·M M Reidenberg, D E Drayer
Jun 1, 1981·Journal of the Royal Society of Medicine·E PeruccaA Richens
Jan 1, 1994·European Journal of Clinical Pharmacology·L Beaulac-Baillargeon, S Rocheleau
Jun 27, 1998·JAMA : the Journal of the American Medical Association·M A Wainberg, G Friedland
Jan 22, 2002·Best Practice & Research. Clinical Obstetrics & Gynaecology·M Dawes, P J Chowienczyk
Mar 22, 2002·Clinical Pharmacology and Therapeutics·Leslie Z Benet, Betty-ann Hoener
Dec 14, 2004·Clinical Pharmacology and Therapeutics·Rolf P G van HeeswijkD William Cameron
Jul 4, 2006·Molecular Biology Reports·Toru UsuiTakaharu Mizutani
Jun 27, 2007·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Kelem KassahunLarissa Wenning
Dec 22, 2007·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·H JeongJames H Fischer
Mar 13, 2009·Clinical Pharmacology and Therapeutics·Larissa WenningM Iwamoto
Jul 8, 2010·Expert Opinion on Drug Metabolism & Toxicology·Pietro PalatiniSara De Martin
Dec 1, 2010·Antimicrobial Agents and Chemotherapy·Masanori KobayashiTamio Fujiwara
Feb 26, 2011·Clinical Pharmacokinetics·Srinivasan RamanathanBrian P Kearney
Mar 12, 2011·The Journal of Antimicrobial Chemotherapy·Nadine Cécile Luise ZembruskiJohanna Weiss
Apr 5, 2011·AIDS Research and Human Retroviruses·Carolina GarridoSinres Team
Jul 13, 2011·Antimicrobial Agents and Chemotherapy·Lingzhi WangLawrence Lee
Mar 1, 2012·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Shujuan ChenRobert H Tukey
Mar 21, 2012·Antimicrobial Agents and Chemotherapy·Matthew L RizkLarissa Wenning
Jul 28, 2012·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Su-Young ChoiHyunyoung Jeong
Aug 1, 2012·British Journal of Clinical Pharmacology·Aida KuloCatherijne A J Knibbe
Dec 12, 2012·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Ioannis PapageorgiouJashvant D Unadkat
Jan 24, 2013·PloS One·Peter MessiaenLinos Vandekerckhove
Jan 29, 2013·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Alice Ban KeJashvant D Unadkat
May 15, 2013·Antimicrobial Agents and Chemotherapy·Stephen CastellinoPaul M Savina
Jul 5, 2013·Clinical Pharmacokinetics·Mackenzie L CottrellAngela D M Kashuba
Jul 17, 2013·Antimicrobial Agents and Chemotherapy·Caroline BarauAurélie Barrail-Tran
Aug 29, 2013·Biochemical and Biophysical Research Communications·Yumi HashiguchiHideyuki Saito
Dec 4, 2013·Clinical Pharmacokinetics·James H FischerKeith A Rodvold
Feb 20, 2014·Antimicrobial Agents and Chemotherapy·Joseph M CustodioSrinivasan Ramanathan
Aug 12, 2010·ACS Medicinal Chemistry Letters·Lianhong XuManoj C Desai
Aug 28, 2014·Journal of Acquired Immune Deficiency Syndromes : JAIDS·D Heather WattsIMPAACT 1026s study team
Sep 10, 2014·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Mahamad Yunnus A MahatShilpee Chaudhary


Nov 1, 2019·Expert Opinion on Drug Metabolism & Toxicology·Dario CattaneoGiuliano Rizzardini
Feb 1, 2020·Therapeutic Drug Monitoring·Brendan OʼKellyJohn S Lambert
Apr 10, 2020·Expert Opinion on Drug Metabolism & Toxicology·Megan NearyAdeniyi Olagunju
Aug 30, 2020·Drugs·Kimberly K ScarsiCourtney V Fletcher
Sep 3, 2019·Frontiers in Microbiology·Michał S BarskiGoedele N Maertens
Mar 3, 2020·Frontiers in Immunology·Alexander T H CockerMark R Johnson
Oct 29, 2020·Expert Opinion on Pharmacotherapy·Diana Canetti, Vincenzo Spagnuolo
Jul 15, 2020·Antimicrobial Agents and Chemotherapy·Yi ZhengJade Ghosn
Jan 1, 2021·Current Treatment Options in Infectious Diseases·Agnieszka KolakowskaJohann Cailhol
Feb 29, 2020·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Cordula StillhartAnette Müllertz

Methods Mentioned


Related Concepts

Trending Feeds


Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Hereditary Sensory Autonomic Neuropathy

Hereditary Sensory Autonomic Neuropathies are a group of inherited neurodegenerative disorders characterized clinically by loss of sensation and autonomic dysfunction. Here is the latest research on these neuropathies.

Spatio-Temporal Regulation of DNA Repair

DNA repair is a complex process regulated by several different classes of enzymes, including ligases, endonucleases, and polymerases. This feed focuses on the spatial and temporal regulation that accompanies DNA damage signaling and repair enzymes and processes.

Glut1 Deficiency

Glut1 deficiency, an autosomal dominant, genetic metabolic disorder associated with a deficiency of GLUT1, the protein that transports glucose across the blood brain barrier, is characterized by mental and motor developmental delays and infantile seizures. Follow the latest research on Glut1 deficiency with this feed.

Separation Anxiety

Separation anxiety is a type of anxiety disorder that involves excessive distress and anxiety with separation. This may include separation from places or people to which they have a strong emotional connection with. It often affects children more than adults. Here is the latest research on separation anxiety.

KIF1A Associated Neurological Disorder

KIF1A associated neurological disorder (KAND) is a rare neurodegenerative condition caused by mutations in the KIF1A gene. KAND may present with a wide range and severity of symptoms including stiff or weak leg muscles, low muscle tone, a lack of muscle coordination and balance, and intellectual disability. Find the latest research on KAND here.

Regulation of Vocal-Motor Plasticity

Dopaminergic projections to the basal ganglia and nucleus accumbens shape the learning and plasticity of motivated behaviors across species including the regulation of vocal-motor plasticity and performance in songbirds. Discover the latest research on the regulation of vocal-motor plasticity here.